Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454073 | 1.00 | MEN1 (0.46) | MEN1POLBKMT2AGRM5CHRNB2 | |
| SCHEMBL16904329 | 0.85 | CHRNB2 (0.40) | MEN1POLBKMT2AGRM5CHRNB2 | |
| SCHEMBL11566792 | 0.80 | CHRNB2 (0.41) | MEN1POLBKMT2ACHRNB2CHRNA4 | |
| SCHEMBL189015 | 0.80 | LMNA (0.47) | CHRNB2CHRNA4LMNASMN1; SMN2MET | |
| SCHEMBL30320472 | 0.80 | LMNA (0.47) | CHRNB2CHRNA4LMNASMN1; SMN2MET | |
| SCHEMBL24752408 | 0.78 | CHRNB2 (0.39) | MEN1POLBKMT2ACHRNB2CHRNA4 | |
| SCHEMBL30853057 | 0.78 | CHRNB2 (0.39) | MEN1POLBKMT2ACHRNB2CHRNA4 | |
| SCHEMBL29189625 | 0.78 | CHRNB2 (0.39) | MEN1POLBKMT2ACHRNB2CHRNA4 | |
| SCHEMBL9965980 | 0.78 | GRM5 (0.50) | MEN1POLBKMT2AGRM5CHRNB2 | |
| SCHEMBL9963327 | 0.78 | MEN1 (0.47) | MEN1POLBKMT2AGRM5NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| CN-102574845-B | 1H-imidazo [4,5-c] qualone derivative | NOVARTIS AG (CH) | 2015-09-02 | — | — | CN | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| CN-103403004-A | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA | 2013-11-20 | — | — | CN | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | MEN1 762/4885POLB 2556/4885KMT2A 1106/4885 |
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ADH1A, ADH1C, ADH5 | MEN1 651/4885POLB 1012/4885KMT2A 2479/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MEN1 3285/4885POLB 4228/4885KMT2A 1019/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MEN1 3285/4885POLB 4228/4885KMT2A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.